Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease

Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease

Abstract Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effect of LCIG on Advanced Parkinson’s Disease (APD) patients QoL. Secondarily...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Francesc Valldeoriola, María José Catalán, Francisco Escamilla-Sevilla, Eric Freire, Jesús Olivares, Esther Cubo, Diego Santos García, Matilde Calopa, Pablo Martínez-Martín, Juan Carlos Parra, Gloria Arroyo, José Matías Arbelo
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Neurology. Diseases of the nervous system
RC346-429
Accès en ligne:https://doaj.org/article/b29e73979abe4d5b826cdca39dd2e61d
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/b29e73979abe4d5b826cdca39dd2e61d

Documents similaires